Fulgent Genetics, Inc. (FLGT) stock
Close on Nov 12, 2026Market cap $683.76MP/E –Yield –
Fulgent Genetics, Inc. grew revenue 4.7% to $330.28M over the twelve months to Sep 30, 2026. Free cash flow was -$1.40M. At the latest close the market valued the company at $683.76M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $683.76M
- P/E ratio
- –
- Price to sales
- 2.07
- Price to book
- 0.69
- Dividend yield
- –
- Free cash flow yield
- -0.20%
Fundamentals
- Revenue
- $330.28M
- Net income
- -$90.93M
- EPS, diluted
- -$3.09
- Free cash flow
- -$1.40M
- Book value per share
- $35.81
- Diluted shares
- 28M
Trading
- Next earnings
- Feb 26, 2027 (estimated, before the open)
- Previous close
- $25.70
- Open
- $25.41
- Day's range
- $24.55 – $25.73
- Volume
- 287,390
- Average volume (20 days)
- 386,875
- Index membership
- Russell 2000 (since Jun 2020), Russell 3000 (since Aug 2020)
- Beta (5 years)
- 0.89
- 52-week range
- $13.46 – $31.04
- RSI (14 days)
- 63.4
- Volatility (1 year)
- 65.2%
- Relative volume
- 0.91×
- WACC
- 9.3%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | FLGT | S&P 500 | Difference | FLGT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +15.7% | -2.7% | +18.4 pts | ||
| 3 months | +32.8% | -1.7% | +34.6 pts | ||
| Year to date | -5.4% | +11.9% | −17.3 pts | ||
| 1 year | -14.5% | +12.0% | −26.5 pts | ||
| 3 years | -5.1% | +78.2% | −83.3 pts | -1.7% | +21.2% |
| 5 years | -72.0% | +73.2% | −145.3 pts | -22.5% | +11.6% |
| 10 years | +187.3% | +309.6% | −122.4 pts | +11.1% | +15.1% |
Thirteen years at a glance
Fiscal years 2013 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Fulgent Genetics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- News
- News
About Fulgent Genetics
Services-Medical Laboratories
Fulgent is a technology-focused healthcare company operating two primary segments: laboratory services and therapeutic development. Its laboratory business provides anatomic pathology, precision diagnostics including next-generation sequencing, specialized oncology testing, and biopharmaceutical research services, alongside a consumer telemedicine platform called Picture. In its therapeutic segment, the company develops cancer drug candidates and antibody-drug conjugates utilizing a nano-drug encapsulation platform. Fulgent serves institutional clients, including hospitals, healthcare centers, commercial laboratories, government agencies, and corporations, as well as pharmaceutical firms, contract research organizations, health insurers, and individual patients.
Company profile, executives and historyFulgent Genetics stock: common questions
What is Fulgent Genetics's stock price?
FLGT closed at $24.85 on Nov 12, 2026, down 3.31% on the day. Over the past 52 weeks it traded between $13.46 and $31.04.
What is Fulgent Genetics's market cap?
Fulgent Genetics was worth $683.76M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is FLGT's P/E ratio?
Fulgent Genetics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$3.09), so it has no meaningful P/E ratio.
How much revenue does Fulgent Genetics make?
Fulgent Genetics reported revenue of $330.28M for the twelve months to Sep 30, 2026, up 4.7% from a year earlier.
Does Fulgent Genetics pay a dividend?
No. Fulgent Genetics has not paid a cash dividend over the last twelve months.
When does Fulgent Genetics report earnings next?
Fulgent Genetics is expected to report Q4 FY2026 results on Feb 26, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has FLGT stock performed over the past year?
Including dividends, FLGT returned -14.5% over the past year, against +12.0% for the S&P 500.
How many FLGT shares are sold short?
2M shares were sold short at the latest FINRA report, 12.13% of the float, or 7.8 days of average trading volume.
Who are Fulgent Genetics's competitors?
Companies most similar to Fulgent Genetics by business, industry and size include VCYT, CSTL, BNR, PSNL, BLLN.
See a number that looks wrong?